Original Article
Effects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
N Engl J Med 2004; 350:1505-1515April 8, 2004
- Abstract
Background
Decreased high-density lipoprotein (HDL) cholesterol levels constitute a major risk factor for coronary heart disease; however, there are no therapies that substantially raise HDL cholesterol levels. Inhibition of cholesteryl ester transfer protein (CETP) has been proposed as a strategy to raise HDL cholesterol levels.
Methods
We conducted a single-blind, placebo-controlled study to examine the effects of torcetrapib, a potent inhibitor of CETP, on plasma lipoprotein levels in 19 subjects with low levels of HDL cholesterol (<40 mg per deciliter [1.0 mmol per liter]), 9 of whom were also treated with 20 mg of atorvastatin daily. All the subjects received placebo for four weeks and then received 120 mg of torcetrapib daily for the following four weeks. Six of the subjects who did not receive atorvastatin also participated in a third phase, in which they received 120 mg of torcetrapib twice daily for four weeks.
Results
Treatment with 120 mg of torcetrapib daily increased plasma concentrations of HDL cholesterol by 61 percent (P<0.001) and 46 percent (P=0.001) in the atorvastatin and non-atorvastatin cohorts, respectively, and treatment with 120 mg twice daily increased HDL cholesterol by 106 percent (P<0.001). Torcetrapib also reduced low-density lipoprotein (LDL) cholesterol levels by 17 percent in the atorvastatin cohort (P=0.02). Finally, torcetrapib significantly altered the distribution of cholesterol among HDL and LDL subclasses, resulting in increases in the mean particle size of HDL and LDL in each cohort.
Conclusions
In subjects with low HDL cholesterol levels, CETP inhibition with torcetrapib markedly increased HDL cholesterol levels and also decreased LDL cholesterol levels, both when administered as monotherapy and when administered in combination with a statin.
Media in This Article
Figure 1
Mean (±SE) Levels of High-Density Lipoprotein (HDL) Subclasses in Each Group of Subjects during the Placebo and Torcetrapib Phases of the Study.Figure 2
Mean (±SE) Levels of Low-Density Lipoprotein (LDL) Subclasses in Each Group of Subjects during the Placebo and Torcetrapib Phases of the Study.Article Activity
- Article
Large-scale clinical trials in which inhibitors of 3-hydroxy-3-methylglutaryl–coenzyme A reductase (statins) have been used to reduce low-density lipoprotein (LDL) cholesterol levels have shown marked improvements in clinical outcomes.1 Despite the favorable effects of statins on the risk of coronary heart disease, many cardiovascular events are not prevented by statin therapy.2-5 Hence, there is a great deal of interest in identifying therapies capable of further reducing the risk of coronary heart disease. One such potential therapeutic target is a low level of high-density lipoprotein (HDL) cholesterol. A low level of HDL cholesterol is the most common lipid abnormality observed in patients with known coronary heart disease; in about half of these patients this is the primary lipid abnormality.6 Statins have only moderate effects on HDL cholesterol levels, raising them by 5 to 10 percent. Although fibrates and niacin can raise HDL cholesterol levels, the increases are rarely greater than 25 percent. The concept of therapies targeted toward HDL metabolism has gained support with the recent report of a small clinical trial in which five weekly infusions of apolipoprotein A-I Milano–phospholipid complexes induced regression of coronary atherosclerosis, as assessed by intravascular ultrasonography.7,8
Another HDL cholesterol–raising strategy actively being explored is the inhibition of cholesteryl ester transfer protein (CETP). CETP is a plasma glycoprotein that facilitates the transfer of cholesteryl esters from HDL cholesterol to apolipoprotein B–containing lipoproteins.9 Humans with CETP deficiency due to molecular defects in the CETP gene have markedly elevated plasma levels of HDL cholesterol and apolipoprotein A-I,10-12 leading to the concept that CETP inhibition might increase HDL cholesterol levels. In animal models, inhibition of CETP by monoclonal antibodies,13,14 antisense oligonucleotides,15,16 small molecules,17,18 or vaccine-induced antibodies19 has resulted in increased HDL cholesterol levels. In addition, a small-molecule inhibitor of CETP has been shown to increase HDL cholesterol levels to a moderate extent in healthy persons with normal HDL cholesterol levels.20
The current study was designed to examine the effects of a novel CETP inhibitor, torcetrapib, on plasma lipoproteins in patients with a low level of HDL cholesterol (<40 mg per deciliter [1.0 mmol per liter]) when given either alone or in combination with atorvastatin.
Methods
Subjects
The subjects in this investigator-initiated study were recruited at the New England Medical Center, Boston, and the University of Pennsylvania School of Medicine, Philadelphia. Patients were eligible to participate if they met the following criteria: an age between 18 and 70 years, an HDL cholesterol level below 40 mg per deciliter, a triglyceride level below 400 mg per deciliter (4.5 mmol per liter), an LDL cholesterol level of 160 mg per deciliter (4.1 mmol per liter) or less and a body-mass index (the weight in kilograms divided by the square of the height in meters) between 18 and 35. Subjects who had an LDL cholesterol level above 160 mg per deciliter were considered for participation if they met all the inclusion criteria, including an LDL cholesterol level of 160 mg per deciliter or less, once treatment with 20 mg of atorvastatin daily had been started and their plasma lipid levels had stabilized, a step requiring at least two weeks.
Exclusion criteria included the following characteristics: childbearing potential; regular consumption of more than two units of alcohol per week (where one unit consists of 12 oz (360 ml) of beer, 5 oz (150 ml) of wine, or 1 oz (30 ml) of liquor); cigarette smoking; treatment within the previous six weeks with any medication, other than a statin, that is known to affect plasma lipid levels; evidence of renal or endocrine disease (including diabetes) or a strong family history of renal or endocrine disease; a history of hepatic disease or substantial elevations in liver-enzyme levels at the time of screening; congestive heart failure, unstable angina, or myocardial infarction within the previous six months; a clinically relevant electrocardiographic abnormality at the time of screening; and evidence on a urinary screen of illegal drug use.
The study protocol was approved by the human- investigation review committee at each center, and written informed consent was obtained from all the participants. The investigators had complete access to the primary data and conducted the data analysis, which was independently confirmed by investigators at the sponsoring institution.
Study Design and Protocol
This was a single-blind, placebo-controlled, fixed-sequence study designed to examine the effects of torcetrapib on plasma lipoproteins and lipoprotein metabolism in subjects with low HDL cholesterol levels. A total of 19 subjects were enrolled; 9 received atorvastatin, and 10 did not. The study began with an introductory period lasting two to four weeks, during which the subjects were screened and, if their LDL cholesterol level was above 160 mg per deciliter, stabilization with 20 mg of atorvastatin daily had been achieved. All the subjects next received placebo for four weeks, followed by 120 mg of torcetrapib daily for an additional four weeks; a subgroup of the subjects not taking atorvastatin went on to receive 120 mg of torcetrapib twice daily for the following four weeks.
All the subjects underwent a safety evaluation at a clinic visit four weeks after the completion of torcetrapib administration. Blood samples were obtained for safety testing and the measurement of plasma lipid, lipoprotein, and apolipoprotein levels at screening and at weeks 4, 8, 12, and 16, as well as at week 20 in the subgroup that received 120 mg of torcetrapib twice daily.
Biochemical Analysis
Blood samples were collected from the subjects after a 12-to-14-hour fast in tubes containing 0.1 percent EDTA. Plasma was isolated by centrifugation at 2500 rpm at 4°C for 20 minutes. Plasma levels of total cholesterol and triglycerides were measured by enzymatic methods, as previously described.21 The levels of unesterified cholesterol and phospholipid were determined with an AutoAnalyzer (Hitachi 911) and reagent kits (Wako Diagnostics). Plasma levels of esterified cholesterol were calculated by subtracting the unesterified cholesterol level from the total cholesterol level. Plasma LDL cholesterol levels were measured directly with the use of a reagent kit (Genzyme Diagnostics).22 HDL cholesterol levels were determined after dextran sulfate–magnesium precipitation of apolipoprotein B–containing lipoproteins,23 and the cholesterol content of HDL3 (a subclass of HDL cholesterol) was assessed after differential polyanion precipitation.24 Plasma levels of apolipoproteins A-I, A-II, and B were measured on an AutoAnalyzer (Cobas Fara II, Roche) with immunoturbidimetric assays (Wako Diagnostics reagents and calibrators). CETP inhibition in human plasma samples was determined by measuring the transfer of 3H-cholesteryl oleate from HDL to apolipoprotein B–containing lipoproteins and the transfer of 14C-cholesteryl oleate from LDL to HDL. Plasma samples assayed for CETP activity were those collected immediately before the administration of each successive dose of torcetrapib (i.e., at trough), 24 and 12 hours after the last administered dose in the subjects who received once-daily doses and those who received twice-daily doses, respectively.
Nuclear Magnetic Resonance Spectroscopy
Lipoprotein subclass concentrations were determined by proton nuclear magnetic resonance spectroscopy, as previously described.25 For purposes of the current study, subclasses of LDL and HDL were defined as follows: large LDL, 21 to 23 nm; small LDL, 18 to 20 nm; large HDL, 8.8 to 13.0 nm; and small HDL, 7.3 to 7.7 nm.
Statistical Analysis
Because of the large number of end points examined, a uniform method of analysis for all the end points was used. In addition to visual examination of histograms and box plots, the Shapiro–Wilk goodness-of-fit test was used to assess the normality of end-point data.26 No significant departures from normality were detected, with the exception of triglyceride levels, which were log-transformed before analysis. Paired t-tests were used to assess differences between the placebo and drug phases within each group, whereas two-sample t-tests were used to detect statistically significant differences between the subjects who received atorvastatin and those who did not (SPSS software, version 10.0). The percentage change with torcetrapib relative to placebo was computed for individual subjects and summarized descriptively for each group of subjects. The data are presented as means ±SD.
Results
Characteristics of the Subjects
The characteristics of the study subjects at the time of screening are provided in Table 1Table 1
Characteristics of the Subjects at Randomization.. A total of 19 subjects (17 men and 2 women) were enrolled in and completed the trial. The subjects who received atorvastatin and those who did not were similar with respect to age, sex distribution, and levels of HDL cholesterol and apolipoprotein A-I. As expected, the levels of LDL cholesterol and apolipoprotein B were significantly lower in the atorvastatin cohort.Safety and Adverse Events
Torcetrapib, alone or in combination with atorvastatin, resulted in no clinically significant changes in vital signs, serum chemical values, or hematologic values. There were no serious adverse events and no withdrawals due to adverse events. The 19 subjects reported a total of 28 adverse events during the study, 20 of which were mild and 8 of which were moderate. Seventeen of the adverse events, reported by 13 patients, were considered to be treatment related; 14 were mild and 3 were moderate. Four adverse events occurred in three subjects who had received atorvastatin: one had a headache while receiving placebo, two had a headache while receiving 120 mg of torcetrapib daily, and one of the two latter patients also had pain. Thirteen adverse events occurred among the subjects who did not receive atorvastatin: one had dizziness while receiving placebo; six had a headache, asthenia, pain (in two subjects), dyspepsia, herpes simplex, herpes zoster, or sweating while receiving 120 mg of torcetrapib daily; and three had headache, dyspepsia, amnesia, or abnormal thinking while receiving 120 mg of torcetrapib twice daily.
Effects on Plasma Levels of HDL Cholesterol and Apolipoproteins A-I and A-II
Treatment with 120 mg of torcetrapib daily resulted in trough CETP-activity values that were lower than the values measured during placebo administration: the reductions were 38±22 percent (P=0.001) among the subjects who received atorvastatin and 28±16 percent (P=0.003) among those who did not. Among the subjects who also received 120 mg of torcetrapib twice daily, the trough CETP-activity values were 65±16 percent lower than the values measured during the placebo phase (P=0.01). Torcetrapib had striking effects on plasma HDL cholesterol levels (Table 2Table 2
Plasma HDL Cholesterol and Apolipoprotein A-I and A-II Levels at the End of the Placebo and Drug Phases.). At a dose of 120 mg daily, it increased plasma HDL cholesterol levels by 61 percent, from 29±4 mg per deciliter (0.8±0.1 mmol per liter) to 47±10 mg per deciliter (1.2±0.3 mmol per liter), among the subjects who received atorvastatin (P<0.001) and by 46 percent, from 32±7 mg per deciliter (0.8±0.2 mmol per liter) to 46±14 mg per deciliter (1.2±0.4 mmol per liter), among those who did not receive atorvastatin (P=0.001). Among those who went on to receive 120 mg of torcetrapib twice daily, an increase in HDL cholesterol of 106 percent, from 34±5 mg per deciliter (0.9±0.1 mmol per liter) during the placebo phase to 70±15 mg per deciliter (1.8±0.4 mmol per liter), was observed (P<0.001).Plasma levels of the HDL apolipoproteins A-I and A-II were also significantly increased by torcetrapib. Relative to the levels measured during placebo administration, the apolipoprotein A-I and A-II levels increased by 13 percent (P=0.003) and 10 percent (P<0.001), respectively, among the subjects who received 120 mg daily with atorvastatin, by 16 percent (P<0.001) and 12 percent (P=0.01) among those who received 120 mg daily without atorvastatin, and by 36 percent (P<0.001) and 21 percent (P<0.001) among those who received 120 mg twice daily.
Effects of Torcetrapib on Lipids, LDL Cholesterol, and Apolipoprotein B
As shown in Table 3Table 3
Plasma Levels of Lipids, LDL Cholesterol, and Apolipoprotein B at the End of the Placebo and Drug Phases., torcetrapib had minimal effects on the plasma levels of cholesterol and phospholipids. Relative to placebo, torcetrapib at a dose of 120 mg daily in combination with atorvastatin reduced triglyceride levels by 18 percent (P=0.05); the reduction in the subjects who received 120 mg of torcetrapib twice daily was 26 percent (P=0.05).Torcetrapib also reduced plasma levels of LDL cholesterol and apolipoprotein B. Among the subjects who received atorvastatin, torcetrapib reduced LDL cholesterol levels by 17 percent relative to placebo (P=0.02) and reduced apolipoprotein B levels by 14 percent (P=0.002). The corresponding reductions among those who did not receive atorvastatin were 8 percent (P not significant) and 10 percent (P=0.004), respectively. Torcetrapib given at a dose of 120 mg twice daily was associated with nonsignificant reductions in the levels of LDL cholesterol (17 percent) and apolipoprotein B (17 percent) relative to the levels measured during the placebo phase.
Effects of Torcetrapib on HDL and LDL Subclasses
Torcetrapib, as compared with placebo, had marked effects on the lipoprotein subclasses. The HDL2 cholesterol level increased by 323 percent (P<0.001) among the subjects who received atorvastatin and by 87 percent (P=0.02) among those who did not. Among those who went on to receive 120 mg of torcetrapib twice daily, the HDL2 cholesterol level increased by 283 percent over the level measured during the placebo phase (P=0.004). HDL3 cholesterol levels were, likewise, increased by torcetrapib but to a far lesser extent than were the HDL2 cholesterol levels. Torcetrapib increased HDL3 cholesterol levels by 36 percent (P=0.002) among those who received atorvastatin and, among those who did not receive atorvastatin, by 29 percent (P=0.003) and 56 percent (P=0.002) at a dose of 120 mg once daily and a dose of 120 mg twice daily, respectively.
Cholesterol levels within large HDL particles, as assessed by nuclear magnetic resonance spectroscopy, increased by 133 percent over the values measured during the placebo phase (P=0.001) among the subjects who received atorvastatin and by 199 percent among those who did not receive atorvastatin (P=0.001) while receiving torcetrapib at a dose of 120 mg daily; the increase was 446 percent at a dose of 120 mg twice daily (Figure 1Figure 1
Mean (±SE) Levels of High-Density Lipoprotein (HDL) Subclasses in Each Group of Subjects during the Placebo and Torcetrapib Phases of the Study.). The changes in HDL subclass distribution translated into significant increases in the mean diameter of HDL particles among those who received 120 mg daily with atorvastatin (from 8.5±0.20 nm to 9.1±0.33 nm, P=0.002), as well as among those who received 120 mg daily without atorvastatin (from 8.4±0.40 nm to 9.1±0.65 nm, P=0.002); among those who received torcetrapib at a dose of 120 mg twice daily, the diameter increased from 8.4±0.43 nm to 9.7±0.65 nm (P<0.001).Torcetrapib also influenced LDL subclass distribution (Figure 2Figure 2
Mean (±SE) Levels of Low-Density Lipoprotein (LDL) Subclasses in Each Group of Subjects during the Placebo and Torcetrapib Phases of the Study.). Without atorvastatin, torcetrapib at both doses (120 mg once daily and 120 mg twice daily) increased the levels of large LDL particles, by 257 percent (P=0.005) and 294 percent (P=0.03), respectively, relative to placebo. Conversely, the levels of small LDL cholesterol decreased with torcetrapib — by 73 percent at a dose of 120 mg daily without atorvastatin (P=0.04) and by 93 percent at a dose of 120 mg twice daily (P=0.03). Torcetrapib did not significantly alter LDL subclasses in the subjects who received atorvastatin. The changes in LDL-subclass distribution translated into significant increases in the mean diameter of LDL particles at both doses of torcetrapib without atorvastatin, from 20.4±0.89 nm to 21.4±0.79 nm at a dose of 120 mg daily (P=0.002) and from 20.4±0.82 nm to 21.9±0.15 nm at a dose of 120 mg twice daily (P=0.003).Discussion
In the guidelines set forth by the third Adult Treatment Panel of the National Cholesterol Education Program,28 a low HDL cholesterol level is defined categorically as a level below 40 mg per deciliter. The results of clinical trials indicate that even small increases in the HDL cholesterol level can significantly reduce the risk of coronary heart disease.29,30 Primarily on the basis of epidemiologic data, Gordon et al. have reported that an increase in HDL cholesterol by 1 mg per deciliter is associated with a 2 to 4 percent reduction in the risk of cardiovascular events.31 However, there remains a lack of well-tolerated drugs with clinically significant HDL-raising potential.
The current study was designed to examine the effects of a novel CETP inhibitor, torcetrapib, on plasma lipoproteins in patients with a low HDL cholesterol level (<40 mg per deciliter), when given alone or in combination with 20 mg of atorvastatin. Torcetrapib significantly reduced CETP activity, measured at trough, in all subjects. This, in turn, led to marked increases in plasma HDL cholesterol levels, with both doses of torcetrapib (120 mg once daily and 120 mg twice daily) increasing HDL cholesterol from an average of 30±6 mg per deciliter (0.7±0.2 mmol per liter) at base line to 47±10 and 70±15 mg per deciliter, respectively. These values represent approximately the 60th and 99th percentiles for men 50 to 54 years old.32 Because the majority of patients who are candidates for CETP inhibition are also likely to be candidates for statin therapy, it is important to note that torcetrapib raised HDL cholesterol levels effectively in the subjects who also received atorvastatin.
Torcetrapib also reduced LDL cholesterol and apolipoprotein B levels. This finding is consistent with the fact that patients with homozygous defects in the CETP gene have reduced levels of LDL cholesterol.10-12 The metabolic basis for the low levels of LDL cholesterol in persons with CETP deficiency is an increased rate of clearance of LDL cholesterol from the plasma,33 suggesting that the LDL-receptor pathway may be up-regulated in CETP deficiency. Of note, torcetrapib reduced LDL cholesterol levels to a further extent in the subjects who received atorvastatin in this study.
Patients with coronary heart disease have lower levels of large HDL particles27 and higher levels of small, dense LDL particles27,34,35 than do subjects without coronary heart disease. In the current study, concentrations of large HDL particles were significantly elevated by treatment with 120 mg of torcetrapib daily, to a value similar to that seen in age- and sex-matched subjects with normolipidemia.27 This dose of torcetrapib also markedly reduced the levels of small, dense LDL particles both in subjects who had received atorvastatin and those who had not. Thus, the mean particle size of both HDL and LDL was significantly increased by torcetrapib. This result is interesting in the light of the recent report that a CETP polymorphism (replacement of isoleucine at position 405 with valine) that is linked to reduced CETP activity is significantly associated with longevity and large HDL and LDL particle size.36
Recently, the effects of another CETP inhibitor, JTT-705, on plasma lipid levels in humans were reported.20 As reported, slightly hyperlipidemic subjects with normal HDL cholesterol levels were randomly assigned to placebo or daily treatment with 300, 600, or 900 mg of JTT-705. Increases in HDL cholesterol of 16 percent, 25 percent, and 34 percent, respectively, were observed in the three JTT-705 groups. A decrease in LDL cholesterol (by 7 percent) was seen only in the 900-mg group. In contrast, we report the effects of pharmacologic inhibition of CETP on plasma lipids and lipoproteins in patients with low HDL cholesterol levels, including some who also took a statin. Torcetrapib at a dose of 120 mg daily increased HDL cholesterol levels substantially more than did 900 mg of JTT-705, and torcetrapib at a dose of 120 mg twice daily raised HDL cholesterol levels to a level three times as high as did JTT-705. Moreover, the reduction in LDL cholesterol achieved with torcetrapib was more than twice that seen previously with 900 mg of JTT-705.
The relation of CETP activity to the risk of coronary heart disease remains controversial.37 It is not clear whether CETP-deficient persons are protected from coronary heart disease; they may even be at increased risk.38 In the Honolulu Heart Program, a subgroup of persons heterozygous for a functional CETP mutation who had HDL cholesterol levels in the range of 40 to 60 mg per deciliter (1.0 to 1.6 mmol per liter) appeared to be at increased risk for coronary heart disease.38 However, a recent analysis of seven-year prospective data from this study did not reveal a significant relation between heterozygosity for CETP mutations and coronary heart disease or stroke.37 At the population level, it has been reported that a common CETP genetic variant (TaqI B2) is associated with reduced CETP activity, increased HDL cholesterol levels, and a reduced risk of coronary heart disease.39,40 Moreover, inhibition of CETP in rabbits has been found to result in reduced atherosclerosis.16,17,19
In conclusion, torcetrapib is a well-tolerated and effective CETP inhibitor that has pronounced effects on plasma lipoproteins in patients with low HDL cholesterol levels. Torcetrapib not only increased the levels of HDL cholesterol and apolipoprotein A-I, it also reduced the levels of LDL cholesterol and apolipoprotein B, both when given as monotherapy and when given in combination with atorvastatin. Ultimately, the question of whether CETP inhibition is effective in reducing atherosclerotic cardiovascular disease in humans will be resolved only by trials based on hard clinical end points.
Supported in part by the Department of Clinical Research, Medicinal Products Research and Development, Pfizer (Groton, Conn.); by grants from the National Center for Research Resources to the General Clinical Research Center of New England Medical Center (M01-RR00054) and the General Clinical Research Center of the University of Pennsylvania (M01-RR00040); and by a grant (R01-HL60935, to Drs. Brousseau and Schaefer) from the National Heart, Lung, and Blood Institute. Dr. Rader is a recipient of the Burroughs Wellcome Fund Clinical Scientist Award in Translational Research and of a Doris Duke Distinguished Clinical Investigator Award.
Dr. Schaefer reports having received lecture fees, consulting fees, and grant support from AstraZeneca, KOS Pharmaceuticals, and Pfizer. Dr. Rader reports having received lecture and consulting fees from AstraZeneca, KOS Pharmaceuticals, and Pfizer, as well as grant support from Pfizer.
We are indebted to the nursing and dietary staff of each clinical research center as well as to Rodrigo Ferreira, Rose Giordano, Kourosh Hashemi-Zonouz, Judith R. McNamara, Chorthip Nartsupha, Anna Lillethun, and Linda Morrell for excellent technical assistance.
Source Information
From the Lipid Research Laboratory, Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center and Tufts University School of Medicine, Boston (M.E.B., E.J.S.); the Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia (M.L.W., L.T.B., D.J.R.); and the Departments of Cardiovascular and Metabolic Diseases (A.G.D., R.W.C.) and Clinical Biostatistics (J.P.M.), Pfizer, Groton, Conn.
Address reprint requests to Dr. Brousseau at the Lipid Research Laboratory, Division of Endocrinology, Metabolism, Diabetes, and Molecular Medicine, New England Medical Center, 750 Washington St., Box 216, Boston, MA 02111, or at margaret.brousseau@tufts.edu, or to Dr. Rader at the Department of Medicine and Center for Experimental Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104 or at rader@mail.med.upenn.edu.
- References
References
1
Schaefer EJ ,Brousseau ME . Benefits of reducing low-density lipoprotein cholesterol concentrations to <100 mg/dL. Prev Cardiol 2000;3:136-139
CrossRef | Medline2
Scandinavian Simvastatin Survival Study Group
Web of Science | Medline3
Shepherd J ,Cobbe SM ,Ford I , et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307
Full Text | Web of Science | Medline4
Sacks FM ,Pfeffer MA ,Moye LA , et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009
Full Text | Web of Science | Medline5
Downs JR ,Clearfield M ,Weis S , et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/ TexCAPS. JAMA 1998;279:1615-1622
CrossRef | Web of Science | Medline6
Genest JJ ,McNamara JR ,Salem DN ,Schaefer EJ . Prevalence of risk factors in men with premature coronary heart disease. Am J Cardiol 1991;67:1185-1189
CrossRef | Web of Science | Medline7
Nissen SE ,Tsunoda T ,Tuzcu EM , et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003;290:2292-2300
CrossRef | Web of Science | Medline8
Rader DJ . High-density lipoproteins as an emerging therapeutic target for atherosclerosis. JAMA 2003;290:2322-2324
CrossRef | Web of Science | Medline9
Tall AR . Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-1274
Web of Science | Medline10
Brown ML ,Inazu A ,Hesler CB , et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989;342:448-451
CrossRef | Web of Science | Medline11
Koizumi J ,Mabuchi H ,Yoshimura A , et al. Deficiency of serum cholesteryl-ester transfer activity in patients wtih familial hyperalphalipoproteinaemia. Atherosclerosis 1985;58:175-186
CrossRef | Web of Science | Medline12
Inazu A ,Brown ML ,Hesler CB , et al. Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation. N Engl J Med 1990;323:1234-1238
Full Text | Web of Science | Medline13
Whitlock ME ,Swenson TL ,Ramakrishnan R , et al. Monoclonal antibody inhibition of cholesteryl ester transfer protein activity in the rabbit: effects on lipoprotein composition and high density lipoprotein cholesteryl ester metabolism. J Clin Invest 1989;84:129-137
CrossRef | Web of Science | Medline14
Gaynor BJ ,Sand T ,Clark RW ,Aiello RJ ,Bamberger MJ ,Moberly JB . Inhibition of cholesteryl ester transfer protein activity in hamsters alters HDL lipid composition. Atherosclerosis 1994;110:101-109
CrossRef | Web of Science | Medline15
Sugano M ,Makino N . Changes in plasma lipoprotein cholesterol levels by antisense oligodeoxynucleotides against cholesteryl ester transfer protein in cholesterol-fed rabbits. J Biol Chem 1996;271:19080-19083
CrossRef | Web of Science | Medline16
Sugano M ,Makino N ,Sawada S , et al. Effect of antisense oligonucleotides against cholesteryl ester transfer protein on the development of atherosclerosis in cholesterol-fed rabbits. J Biol Chem 1998;273:5033-5036
CrossRef | Web of Science | Medline17
Okamoto H ,Yonemori F ,Wakitani K ,Minowa T ,Maeda K ,Shinkai H . A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000;406:203-207
CrossRef | Web of Science | Medline18
Kothari HV ,Poirier KJ ,Lee WH ,Satoh Y . Inhibition of cholesteryl ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters. Atherosclerosis 1997;128:59-66
CrossRef | Web of Science | Medline19
Rittershaus CW ,Miller DP ,Thomas LJ , et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2106-2112
CrossRef | Web of Science | Medline20
de Grooth GJ ,Kuivenhoven JA ,Stalenhoef AFH , et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 2002;105:2159-2165
CrossRef | Web of Science | Medline21
McNamara JR ,Schaefer EJ . Automated enzymatic standardized lipid analyses for plasma and lipoprotein fractions. Clin Chim Acta 1987;166:1-8
CrossRef | Web of Science | Medline22
McNamara JR ,Cole TG ,Contois JH ,Ferguson CA ,Ordovas JM ,Schaefer EJ . Immunoseparation method for measuring low-density lipoprotein cholesterol directly from serum evaluated. Clin Chem 1995;41:232-240
Web of Science | Medline23
Warnick GR ,Benderson J ,Albers JJ . Dextran sulfate-Mg2+ precipitation procedure for quantitation of high-density-lipoprotein cholesterol. Clin Chem 1982;28:1379-1388
Web of Science | Medline24
Nguyen T ,Warnick GR . Improved methods for separation of total HDL and subclasses. Clin Chem 1989;35:1086-1086 abstract.
Web of Science25
Otvos JD ,Jeyarajah EJ ,Bennett DW ,Krauss RM . Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement. Clin Chem 1992;38:1632-1638
Web of Science | Medline26
Shapiro SS ,Wilk MB . An analysis of variance test for normality (complete samples). Biometrika 1965;52:591-611
Web of Science27
Schaefer EJ ,McNamara JR ,Tayler T , et al. Effects of atorvastatin on fasting and postprandial lipoprotein subclasses in coronary heart disease patients versus control subjects. Am J Cardiol 2002;90:689-696
CrossRef | Web of Science | Medline28
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
CrossRef | Web of Science29
Manninen V ,Elo MO ,Frick MH , et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641-651
CrossRef | Web of Science | Medline30
Robins SJ ,Collins D ,Wittes JT , et al. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001;285:1585-1591
CrossRef | Web of Science | Medline31
Gordon DJ ,Probstfield JL ,Garrison RJ , et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 1989;79:8-15
CrossRef | Web of Science | Medline32
Schaefer EJ ,Lamon-Fava S ,Ordovas JM , et al. Factors associated with low and elevated plasma high density lipoprotein cholesterol and apolipoprotein A-I levels in the Framingham Offspring Study. J Lipid Res 1994;35:871-882
Web of Science | Medline33
Ikewaki K ,Nishiwaki M ,Sakamoto T , et al. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 1995;96:1573-1581
CrossRef | Web of Science | Medline34
Gardner CD ,Fortmann SP ,Krauss RM . Association of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA 1996;276:875-881
CrossRef | Web of Science | Medline35
Lamarche B ,Tchernof A ,Moorjani S , et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men: prospective results from the Québec Cardiovascular Study. Circulation 1997;95:69-75
Web of Science | Medline36
Barzilai N ,Atzmon G ,Schechter C , et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 2003;290:2030-2040
CrossRef | Web of Science | Medline37
Barter PJ ,Brewer HB Jr ,Chapman MJ ,Hennekens CH ,Rader DJ ,Tall AR . Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol 2003;23:160-167
CrossRef | Web of Science | Medline38
Zhong S ,Sharp DS ,Grove JS , et al. Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996;97:2917-2923
CrossRef | Web of Science | Medline39
Ordovas JM ,Cupples LA ,Corella D , et al. Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham Study. Arterioscler Thromb Vasc Biol 2000;20:1323-1329
CrossRef | Web of Science | Medline40
Brousseau ME ,O'Connor JJ Jr ,Ordovas JM , et al. Cholesteryl ester transfer protein TaqI B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency: Veterans Affairs HDL Cholesterol Intervention Trial. Arterioscler Thromb Vasc Biol 2002;22:1148-1154
CrossRef | Web of Science | Medline
- Citing Articles (269)
Citing Articles
1
2011. Enhancement of HDL Formation and Normalization of Intravascular HDL Remodeling. , 423-523.
CrossRef2
2011. Frontmatter. , i-xxxvi.
CrossRef3
Rajesh Sachdeva, Bradley Hughes, Jawahar L. Mehta. 2011. Statins in the Reduction of Cardiovascular Events. .
CrossRef4
Martin Wehling. (2011) Drug development in the light of translational science: shine or shade?. Drug Discovery Today 16:23-24, 1076-1083
CrossRef5
Uchechukwu K. Sampson, Sergio Fazio, MacRae F. Linton. (2011) Residual Cardiovascular Risk Despite Optimal LDL Cholesterol Reduction with Statins: The Evidence, Etiology, and Therapeutic Challenges. Current Atherosclerosis Reports
CrossRef6
Gregory G. Schwartz. (2011) New Horizons for Cholesterol Ester Transfer Protein Inhibitors. Current Atherosclerosis Reports
CrossRef7
Vellaisamy Sridharan, Padmakar A. Suryavanshi, J. Carlos Menéndez. (2011) Advances in the Chemistry of Tetrahydroquinolines. Chemical Reviews 111:11, 7157-7259
CrossRef8
Kristina Duwensee, Stefan Schwaiger, Ivan Tancevski, Kathrin Eller, Miranda van Eck, Patrick Markt, Tobias Linder, Ursula Stanzl, Andreas Ritsch, Josef R. Patsch, Daniela Schuster, Hermann Stuppner, David Bernhard, Philipp Eller. (2011) Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein. Atherosclerosis 219:1, 109-115
CrossRef9
Raul C. Maranhão, Fatima R. Freitas, Célia M. Strunz, Raul D. Santos, Alfredo J. Mansur, Antônio P. Mansur. (2011) Lipid transfers to HDL are predictors of precocious clinical coronary heart disease. Clinica Chimica Acta
CrossRef10
Hayes M. Dansky, Daniel Bloomfield, Patrice Gibbons, Sherry Liu, Christine McCrary Sisk, Diane Tribble, James M. McKenney, Thomas W. Littlejohn, Yale Mitchel. (2011) Efficacy and safety after cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib (MK-0859) in patients with primary hypercholesterolemia or mixed hyperlipidemia. American Heart Journal 162:4, 708-716
CrossRef11
Ronen Gurfinkel, Tisha R. Joy. (2011) Anacetrapib: Hope for CETP Inhibitors?. Cardiovascular Therapeutics 29:5, 327-339
CrossRef12
Marybeth U Allian-Sauer, James M Falko. (2011) Role of apheresis in the management of familial hypercholesterolemia and elevated Lp(a) levels. Clinical Lipidology 6:5, 523-538
CrossRef13
Jennifer B. Christian, Nancy E. Bourgeois, Kimberly A. Lowe. (2011) Prevalence, clinical characteristics and treatment patterns of low high-density lipoprotein cholesterol in the US population. Journal of Cardiovascular Medicine 12:10, 714-722
CrossRef14
Giovanni A. Infusino, Jeffrey R. Jacobson. (2011) Endothelial FAK as a therapeutic target in disease. Microvascular Research
CrossRef15
Ananth Kadambi, Daniel L. Young, Kapil Gadkar. 2011. Systems Modeling Applied to Candidate Biomarker Identification. , 239-263.
CrossRef16
Michael S. Tift, Dorian S. Houser, Daniel E. Crocker. (2011) High-density lipoprotein remains elevated despite reductions in total cholesterol in fasting adult male elephant seals (Mirounga angustirostris). Comparative Biochemistry and Physiology Part B: Biochemistry and Molecular Biology 159:4, 214-219
CrossRef17
Cameron J. Smith, Amjad Ali, Milton L. Hammond, Hong Li, Zhijian Lu, Joann Napolitano, Gayle E. Taylor, Christopher F. Thompson, Matt S. Anderson, Ying Chen, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Carl P. Sparrow, Samuel D. Wright, Anne-Marie Cumiskey, Melanie Latham, Laurence B. Peterson, Ray Rosa, James V. Pivnichny, Xinchun Tong, Suoyu S. Xu, Peter J. Sinclair. (2011) Biphenyl-Substituted Oxazolidinones as Cholesteryl Ester Transfer Protein Inhibitors: Modifications of the Oxazolidinone Ring Leading to the Discovery of Anacetrapib. Journal of Medicinal Chemistry 54:13, 4880-4895
CrossRef18
Olaf Weber, Stefan Willmann, Hilmar Bischoff, Volkhart Li, Alexandros Vakalopoulos, Klemens Lustig, Frank-Thorsten Hafner, Roland Heinig, Carsten Schmeck, Klaus Buehner. (2011) Prediction of a Potentially Effective Dose in Humans for BAY 60-5521, a Potent Inhibitor of Cholesteryl Ester Transfer Protein (CETP) by Allometric Species Scaling and Combined Pharmacodynamic and Physiologically-Based Pharmacokinetic Modelling. British Journal of Clinical Pharmacologyno-no
CrossRef19
Christopher F. Thompson, Amjad Ali, Nazia Quraishi, Zhijian Lu, Milton L. Hammond, Peter J. Sinclair, Matt S. Anderson, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Carl P. Sparrow, Samuel D. Wright. (2011) Discovery of Substituted Biphenyl Oxazolidinone Inhibitors of Cholesteryl Ester Transfer Protein. ACS Medicinal Chemistry Letters 2:6, 424-427
CrossRef20
A.D. Dergunov. (2011) Apolipoprotein E genotype as a most significant predictor of lipid response at lipid-lowering therapy: Mechanistic and clinical studies. Biomedicine & Pharmacotherapy
CrossRef21
Ramzi F. Sweis, Julianne A. Hunt, Peter J. Sinclair, Ying Chen, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Anne-Marie Cumiskey, Melanie Latham, Raymond Rosa, Larry Peterson, Carl P. Sparrow, Matt S. Anderson. (2011) 2-(4-Carbonylphenyl)benzoxazole inhibitors of CETP: Attenuation of hERG binding and improved HDLc-raising efficacy. Bioorganic & Medicinal Chemistry Letters 21:9, 2597-2600
CrossRef22
Helena C. F. Oliveira, Eliana C. de Faria. (2011) Cholesteryl ester transfer protein: The controversial relation to atherosclerosis and emerging new biological roles. IUBMB Life 63:4, 248-257
CrossRef23
Carlos G Santos-Gallego, Francisco Torres, Juan José Badimón. (2011) The beneficial effects of HDL-C on atherosclerosis: rationale and clinical results. Clinical Lipidology 6:2, 181-208
CrossRef24
Alberto Dávalos, Carlos Fernández-Hernando. (2011) microRNAs, Plasma Lipids, and Cardiovascular Disease. Current Cardiovascular Risk Reports 5:1, 10-17
CrossRef25
Steven E. Nissen. (2011) Atherosclerosis in 2010: New therapeutic insights. Nature Reviews Cardiology 8:2, 70-72
CrossRef26
Hao Wang, Dao-Quan Peng. (2011) New insights into the mechanism of low high-density lipoprotein cholesterol in obesity. Lipids in Health and Disease 10:1, 176
CrossRef27
Alexandros Vakalopoulos, Carsten Schmeck, Michael Thutewohl, Volkhart Li, Hilmar Bischoff, Klemens Lustig, Olaf Weber, Holger Paulsen, Harry Elias. (2011) Chromanol derivatives—A novel class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 21:1, 488-491
CrossRef28
Cannon, Christopher P., Shah, Sukrut, Dansky, Hayes M., Davidson, Michael, Brinton, Eliot A., Gotto, Antonio M. Jr., Stepanavage, Michael, Liu, Sherry Xueyu, Gibbons, Patrice, Ashraf, Tanya B., Zafarino, Jennifer, Mitchel, Yale, Barter, Philip, . (2010) Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease. New England Journal of Medicine 363:25, 2406-2415
Full Text29
Andrea J. Luthi, Pinal C. Patel, Caroline H. Ko, R. Kannan Mutharasan, Chad A. Mirkin, C. Shad Thaxton. (2010) Nanotechnology for synthetic high-density lipoproteins. Trends in Molecular Medicine 16:12, 553-560
CrossRef30
Rajesh Krishna, John A Wagner. (2010) Applications of ‘decisionable’ biomarkers in cardiovascular drug development. Biomarkers in Medicine 4:6, 815-827
CrossRef31
Ira G. Schulman. (2010) Nuclear receptors as drug targets for metabolic disease. Advanced Drug Delivery Reviews 62:13, 1307-1315
CrossRef32
Amjad Ali, Julianne A. Hunt, Peter J. Sinclair. 2010. Atherosclerosis II: HDL Elevation. .
CrossRef33
Justin MS Lee, Robin P Choudhury. (2010) Atherosclerosis regression and high-density lipoproteins. Expert Review of Cardiovascular Therapy 8:9, 1325-1334
CrossRef34
Shin-ichiro Miura, Keijiro Saku. (2010) Is a blood pressure rise the only deleterious off-target effect of cholesterol ester transfer protein inhibitors?. Journal of Hypertension 28:8, 1614-1616
CrossRef35
Amit V. Khera, Megan L. Wolfe, Christopher P. Cannon, Jie Qin, Daniel J. Rader. (2010) On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 [PROVE IT-TIMI 22] Study). The American Journal of Cardiology 106:4, 451-456
CrossRef36
2010. Blood Lipid Abnormalities. , 136-141.
CrossRef37
Karen L Andrews, Xiao L Moore, Jaye PF Chin-Dusting. (2010) Anti-atherogenic effects of high-density lipoprotein on nitric oxide synthesis in the endothelium. Clinical and Experimental Pharmacology and Physiology 37:7, 736-742
CrossRef38
Kristina Duwensee, Lutz Philipp Breitling, Ivan Tancevski, Dietrich Rothenbacher, Egon Demetz, Josef R. Patsch, Andreas Ritsch, Philipp Eller, Hermann Brenner. (2010) Cholesteryl ester transfer protein in patients with coronary heart disease. European Journal of Clinical Investigation 40:7, 616-622
CrossRef39
Courtney B. Sherman, Stephen J. Peterson, William H. Frishman. (2010) Apolipoprotein A-I Mimetic Peptides. Cardiology in Review 18:3, 141-147
CrossRef40
Stephen J. Nicholls, Pia Lundman, Jean-Claude Tardif. (2010) Diabetic dyslipidemia: extending the target beyond LDL cholesterol. European Journal of Cardiovascular Prevention & Rehabilitation 17, S20-S24
CrossRef41
F. Civeira, R. Mateo-Gallego, E. Burillo, A. Cenarro. (2010) La elevación del colesterol unido a lipoproteínas de alta densidad: perspectiva futura. La CETP como diana terapéutica. Clínica e Investigación en Arteriosclerosis 22, 44-48
CrossRef42
P. Aguiar-Souto, J.R. González-Juanatey. (2010) Torcetrapib: una perspectiva histórica. Clínica e Investigación en Arteriosclerosis 22, 49-54
CrossRef43
Juan José Badimón, Borja Ibáñez. (2010) Incremento de las HDL como arma terapéutica en la aterotrombosis. Revista Española de Cardiología 63:3, 323-333
CrossRef44
Pradeep Natarajan, Kausik K. Ray, Christopher P. Cannon. (2010) High-Density Lipoprotein and Coronary Heart Disease. Journal of the American College of Cardiology 55:13, 1283-1299
CrossRef45
Arnold von Eckardstein. (2010) Implications of torcetrapib failure for the future of HDL therapy: is HDL-cholesterol the right target?. Expert Review of Cardiovascular Therapy 8:3, 345-358
CrossRef46
Canan Ersoy, Ganime Sadikoglu, Hasan Orhan, Metin Guclu, Emre Sarandol, Meral Demirci Akgun, Alis Ozcakir, Sazi Imamoglu. (2010) Body fat distribution has no effect on serum visfatin levels in healthy female subjects. Cytokine 49:3, 275-278
CrossRef47
Marit Westerterp, Joris Koetsveld, Alan R Tall. (2010) CETP Inhibition: a Dysfunctional Endothelium?. Journal of Cardiovascular Pharmacology1
CrossRef48
Aihua Wang, Catherine P. Prouty, Patricia D. Pelton, Maria Yong, Keith T. Demarest, William V. Murray, Gee-Hong Kuo. (2010) Synthesis and discovery of 2,3-dihydro-3,8-diphenylbenzo[1,4]oxazines as a novel class of potent cholesteryl ester transfer protein inhibitors. Bioorganic & Medicinal Chemistry Letters 20:4, 1432-1435
CrossRef49
Aaron M. Brown, David L. Schriger, Tyler W. Barrett. (2010) Outcome Measures, Interim Analyses, and Bayesian Approaches to Randomized Trials. Annals of Emergency Medicine 55:2, 216-224.e1
CrossRef50
Cameron J. Smith, Amjad Ali, Liya Chen, Milton L. Hammond, Matt S. Anderson, Ying Chen, Suzanne S. Eveland, Qiu Guo, Sheryl A. Hyland, Denise P. Milot, Carl P. Sparrow, Samuel D. Wright, Peter J. Sinclair. (2010) 2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety. Bioorganic & Medicinal Chemistry Letters 20:1, 346-349
CrossRef51
Margery A Connelly, Tom J Parry, Edward C Giardino, Zhihong Huang, Wai-man Cheung, Cailin Chen, Frank Cools, Henk Van der Linde, David J Gallacher, Gee-Hong Kuo, Troy C Sarich, Keith T Demarest, Bruce P Damiano. (2009) Torcetrapib Produces Endothelial Dysfunction Independent of CETP Inhibition. Journal of Cardiovascular Pharmacology1
CrossRef52
James S Polakowski, Andrew J King, Thomas J Campbell, Richard A Nelson, Lee C Preusser, Anita J Kempf-Grote, Kennan C Marsh, Gary A Gintant, Bryan F Cox, Scott W Mittelstadt. (2009) Cardiovascular Effects of Torcetrapib in Conscious and Pentobarbital-anesthetized Dogs. Journal of Cardiovascular Pharmacology 54:6, 543-551
CrossRef53
Mariann Harangi, Ildikó Seres, János Harangi, György Paragh. (2009) Benefits and Difficulties in Measuring HDL Subfractions and Human Paraoxonase-1 Activity During Statin Treatment. Cardiovascular Drugs and Therapy 23:6, 501-510
CrossRef54
D. Sander, T. Etgen. (2009) Sekundärprophylaxe des Schlaganfalls nach PRoFESS und SPARCL. Der Internist 50:11, 1227-1238
CrossRef55
R Wolk, D Chen, R W Clark, J Mancuso, P L Barclay. (2009) Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects. Clinical Pharmacology & Therapeutics 86:4, 430-437
CrossRef56
R Olufadi, SH Wild, CD Byrne. 2009. Cholesterol Metabolism and Vascular Disease. .
CrossRef57
Xavier Pillois, Nahm Phuong Do Thi, Annabel Reynaud, Daniel Benchimol, Laurent Lagrost, Jacques Bonnet. (2009) TaqIB polymorphism in cholesterol ester transfer protein ( CETP ) gene predicts future cardiovascular death in patients experiencing an acute coronary syndrome. Clinical Chemistry and Laboratory Medicine 47:9, 1039-1046
CrossRef58
Derek J Hausenloy, Derek M Yellon. (2009) Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Current Opinion in Cardiology 24:5, 473-482
CrossRef59
Henry N. Ginsberg, Paul R. MacCallum. (2009) The Obesity, Metabolic Syndrome, and Type 2 Diabetes Mellitus Pandemic: II. Therapeutic Management of Atherogenic Dyslipidemia. The Journal of Clinical Hypertension 11:9, 520-527
CrossRef60
Diana R. Chirovsky, Veronika Fedirko, Yadong Cui, Vasilisa Sazonov, Philip Barter. (2009) Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. European Journal of Cardiovascular Prevention & Rehabilitation 16:4, 404-423
CrossRef61
Graham C. Burdge, Jonathan Powell, Tony Dadd, Duncan Talbot, Jacqueline Civil, Philip C. Calder. (2009) Acute consumption of fish oil improves postprandial VLDL profiles in healthy men aged 50–65 years. British Journal of Nutrition 102:01, 160
CrossRef62
Danielle Duffy, Daniel J. Rader. (2009) Update on strategies to increase HDL quantity and function. Nature Reviews Cardiology 6:7, 455-463
CrossRef63
Patrick M Moriarty. (2009) Association of ApoE and HDL-C with cardiovascular and cerebrovascular disease: potential benefits of LDL-apheresis therapy. Clinical Lipidology 4:3, 311-329
CrossRef64
David Preiss, Naveed Sattar. (2009) Lipids, lipid modifying agents and cardiovascular risk: a review of the evidence. Clinical Endocrinology 70:6, 815-828
CrossRef65
Eileen Blasi, Mark Bamberger, Delvin Knight, Mike Engwall, Robert Wolk, Steven Winter, Allison Betts, Annette John-Baptiste, Joan Keiser. (2009) Effects of CP-532,623 and Torcetrapib, Cholesteryl Ester Transfer Protein Inhibitors, on Arterial Blood Pressure. Journal of Cardiovascular Pharmacology 53:6, 507-516
CrossRef66
Mariann Harangi, Hossein Z. Mirdamadi, Ildikó Seres, Ferenc Sztanek, Miklós Molnár, Andrea Kassai, Zoltán Derdák, László Illyés, György Paragh. (2009) Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity. Translational Research 153:4, 190-198
CrossRef67
Jeffrey R. Jacobson. (2009) Statins in Endothelial Signaling and Activation. Antioxidants & Redox Signaling 11:4, 811-821
CrossRef68
Ki-Hoon Han. (2009) Control of Dyslipidemia. Journal of the Korean Medical Association 52:3, 299
CrossRef69
John C. Alexander, Daniel E. Salazar. 2009. Modern Drug Discovery and Development. , 361-380.
CrossRef70
Christopher W. Knouff, Noha Lim, Kijoung Song, Xin Yuan, Max C. Walker, Ray Townsend, Gerard Waeber, Paul M. Matthews, Peter Vollenweider, Dawn M. Waterworth, Vincent Mooser. (2008) Pharmacological effects of lipid-lowering drugs recapitulate with a larger amplitude the phenotypic effects of common variants within their target genes. Pharmacogenetics and Genomics 18:12, 1051-1057
CrossRef71
D. Ye, A. O. Kraaijeveld, R. W. Grauss, S. M. Willems, L. C. van Vark-van der Zee, S. C. A. de Jager, M. Jauhiainen, J. A. Kuivenhoven, G. M. Dallinga-Thie, D. E. Atsma, P. C. W. Hogendoorn, E. A. L. Biessen, T. J. C. Van Berkel, J. W. Jukema, M. van Eck. (2008) Reduced leucocyte cholesteryl ester transfer protein expression in acute coronary syndromes. Journal of Internal Medicine 264:6, 571-585
CrossRef72
Atul Tiwari. (2008) Current and emerging paradigms in the therapeutic management of atherosclerosis. Expert Opinion on Therapeutic Targets 12:12, 1523-1546
CrossRef73
D John Betteridge. (2008) Lipid lowering in diabetes mellitus. Current Opinion in Lipidology 19:6, 579-584
CrossRef74
Jan A Krikken, Geesje M Dallinga-Thie, Gerjan Navis, Robin PF Dullaart. (2008) Renin–angiotensin–aldosterone responsiveness to low sodium and blood pressure reactivity to angiotensin-II are unrelated to cholesteryl ester transfer protein mass in healthy subjects. Expert Opinion on Therapeutic Targets 12:11, 1321-1328
CrossRef75
C. Roger White, Geeta Datta, Zhenghao Zhang, Himanshu Gupta, David W. Garber, Vinod K. Mishra, Mayakonda N. Palgunachari, Shaila P. Handattu, Manjula Chaddha, G. M. Anantharamaiah. (2008) HDL therapy for cardiovascular diseases: the road to HDL mimetics. Current Atherosclerosis Reports 10:5, 405-412
CrossRef76
Sheila A Doggrell. (2008) The failure of torcetrapib: is there a case for independent preclinical and clinical testing? – author's reply. Expert Opinion on Pharmacotherapy 9:14, 2563-2564
CrossRef77
William T. Cefalu. (2008) Diabetic dyslipidemia and the metabolic syndrome. Diabetes and Metabolic Syndrome: Clinical Research and Reviews 2:3, 208-222
CrossRef78
James K. Liao. (2008) Clinical trials report. Current Atherosclerosis Reports 10:4, 281-283
CrossRef79
Ekaterini Vourvouhaki, George V Dedoussis. (2008) Cholesterol ester transfer protein: a therapeutic target in atherosclerosis?. Expert Opinion on Therapeutic Targets 12:8, 937-948
CrossRef80
Fergus McTaggart, Peter Jones. (2008) Effects of Statins on High-Density Lipoproteins: A Potential Contribution to Cardiovascular Benefit. Cardiovascular Drugs and Therapy 22:4, 321-338
CrossRef81
Zuhier Awan, Khalid Al. Waili, Khalid Alrasadi, Jacques Genest. (2008) Treatment of low high-density lipoprotein cholesterol. Canadian Journal of Cardiology 24, 27C-31C
CrossRef82
M J Forrest, D Bloomfield, R J Briscoe, P N Brown, A-M Cumiskey, J Ehrhart, J C Hershey, W J Keller, X Ma, H E McPherson, E Messina, L B Peterson, W Sharif-Rodriguez, P K S Siegl, P J Sinclair, C P Sparrow, A S Stevenson, S-Y Sun, C Tsai, H Vargas, M Walker, S H West, V White, R F Woltmann. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. British Journal of Pharmacology 154:7, 1465-1473
CrossRef83
Peter O. Kwiterovich. (2008) Clinical and laboratory assessment of cardiovascular risk in children: Guidelines for screening, evaluation, and treatment. Journal of Clinical Lipidology 2:4, 248-266
CrossRef84
Thomas P. Beyer, Yanqun Chen, Regina K. Porter, Deshun Lu, Robert J. Schmidt, Nathan B. Mantlo, Robert J. Konrad, Guoqing Cao. (2008) Peroxisome Proliferator-Activated Receptor α Agonists Regulate Cholesterol Ester Transfer Protein. Lipids 43:7, 611-618
CrossRef85
Stephen J Nicholls, E Murat Tuzcu. (2008) High-density lipoprotein and atheroma monitoring. Current Opinion in Cardiology 23:4, 386-392
CrossRef86
Valmore Bermúdez, Raquel Cano, Clímaco Cano, Fernando Bermúdez, Nailet Arraiz, Luis Acosta, Freddy Finol, María Rebeca Pabón, Anilsa Amell, Nadia Reyna, Joaquin Hidalgo, Paúl Kendall, Velasco Manuel, Rafael Hernández. (2008) Pharmacologic Management of Isolated Low High-Density Lipoprotein Syndrome. American Journal of Therapeutics 15:4, 377-388
CrossRef87
Daniel L. Sparks, Cynthia Chatterjee, Elizabeth Young, Joanna Renwick, Nihar R. Pandey. (2008) Lipoprotein charge and vascular lipid metabolism. Chemistry and Physics of Lipids 154:1, 1-6
CrossRef88
Justin M. S. Lee, Alistair C. Lindsay, Ilias Kylintireas, Robin P. Choudhury. (2008) Atherosclerosis regression. Current Treatment Options in Cardiovascular Medicine 10:3, 187-194
CrossRef89
Nerses Sanossian, Nicholas E. Tarlov. (2008) HDL-C and LDL-C: Their role in stroke pathogenesis and implications for treatment. Current Treatment Options in Cardiovascular Medicine 10:3, 195-206
CrossRef90
Robert S. Rosenson. (2008) Off-target toxicity: Risks associated with adrenal corticoid activation in ILLUMINATE. Current Atherosclerosis Reports 10:3, 227-229
CrossRef91
Alan R. Tall, Laurent Yvan-Charvet, Naoki Terasaka, Tamara Pagler, Nan Wang. (2008) HDL, ABC Transporters, and Cholesterol Efflux: Implications for the Treatment of Atherosclerosis. Cell Metabolism 7:5, 365-375
CrossRef92
Paola Conca, Guido Franceschini. (2008) Synthetic HDL as a new treatment for atherosclerosis regression: Has the time come?. Nutrition, Metabolism and Cardiovascular Diseases 18:4, 329-335
CrossRef93
Rakhi Shah Barkowski, William H. Frishman. (2008) HDL Metabolism and CETP Inhibition. Cardiology in Review 16:3, 154-162
CrossRef94
SHADWAN ALSAFWAH, KODANGUDI B. RAMANATHAN. (2008) Can We Cause Regression of Coronary Atherosclerosis?. The American Journal of the Medical Sciences 335:5, 368-374
CrossRef95
Scott Kinlay. 2008. Vascular Biology. , 1-10.
CrossRef96
Sheila A Doggrell. (2008) The failure of torcetrapib: is there a case for independent preclinical and clinical testing?. Expert Opinion on Pharmacotherapy 9:6, 875-878
CrossRef97
Madiha Abdel-Maksoud, Vasilisa Sazonov, Stephen W Gutkin, John E Hokanson. (2008) Effects of Modifying Triglycerides and Triglyceride-rich Lipoproteins on Cardiovascular Outcomes. Journal of Cardiovascular Pharmacology 51:4, 331-351
CrossRef98
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:2, 115-125
CrossRef99
Han-Soo Park, Jong-Il Kim, Sung-Il Cho, Joo-Hon Sung, Hyung-Lae Kim, Young-Seok Ju, Gombojav Bayasgalan, Mi-Kyeong Lee, Jeong-Sun Seo. (2008) Genome-wide Linkage Study for Plasma HDL Cholesterol Level in an Isolated Population of Mongolia. Genomics & Informatics 6:1, 8-13
CrossRef100
Pitchai Balakumar, Tajpreet Kaur, Manjeet Singh. (2008) Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology 245:1-2, 49-64
CrossRef101
Christopher J. O’Donnell, Roberto Elosua. (2008) Factores de riesgo cardiovascular. Perspectivas derivadas del Framingham Heart Study. Revista Española de Cardiología 61:3, 299-310
CrossRef102
Daniel J. Rader, Alan Daugherty. (2008) Translating molecular discoveries into new therapies for atherosclerosis. Nature 451:7181, 904-913
CrossRef103
Ramya S Suryadevara, Richard H Karas, Jeffrey T Kuvin. (2008) Use of extended-release niacin in clinical practice. Future Lipidology 3:1, 9-16
CrossRef104
J. Willeit, S. Kiechl, F. Aichner, K. Berek, H. Binder, M. Brainin, F. Fazekas, G. Fraedrich, H.P. Haring, S. Horner, B. Iglseder, P. Kapeller, W. Lang, E. Minar, K. Niederkorn, G. Noisternig, M. Schillinger, R. Schmidt, E. Schmutzhard, P. Waldenberger, H.W. Wege. (2008) Positionspapier der Österreichischen Gesellschaft für Schlaganfallforschung. Gefässchirurgie 13:1, 31-41
CrossRef105
G. Jackson. (2008) Torcetrapib: when global risk reduction goes ‘off target’. International Journal of Clinical Practice 62:2, 173-174
CrossRef106
Michael Clearfield. (2008) Clinical trials report. Current Atherosclerosis Reports 10:1, 5-10
CrossRef107
Guido Franceschini, Laura Calabresi. (2008) Raising HDL cholesterol for cardiovascular disease prevention: Is this still feasible?. Current Cardiovascular Risk Reports 2:1, 35-40
CrossRef108
María Luisa García de Aguinaga, Manuel Posada de la Paz, Eva Estirado de Cabo, María del Mar Plaza Cano, Carmen Suárez Álvarez, Beatriz Braun Saro, Ignacio Abaitua Borda, Rafael Gabriel Sánchez, Francisco Javier Barbado Hernández. (2008) High prevalence of cardiovascular risk in patients with toxic oil syndrome: A comparative study using the general Spanish population. European Journal of Internal Medicine 19:1, 32-39
CrossRef109
Shinichi Okamura, Yoshie Sawada, Teturou Satoh, Hironosuke Sakamoto, Yuichiro Saito, Hiroyuki Sumino, Takako Takizawa, Toshiaki Kogure, Chiayo Chaichantipyuth, Yoshihiro Higuchi, Tsutomu Ishikawa, Tetsuo Sakamaki. (2008) Pueraria Mirifica Phytoestrogens Improve Dyslipidemia in Postmenopausal Women Probably by Activating Estrogen Receptor Subtypes. The Tohoku Journal of Experimental Medicine 216:4, 341-351
CrossRef110
Bela F. Asztalos, Dorothea Collins, Katalin V. Horvath, Hanna E. Bloomfield, Sander J. Robins, Ernst J. Schaefer. (2008) Relation of gemfibrozil treatment and high-density lipoprotein subpopulation profile with cardiovascular events in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Metabolism 57:1, 77-83
CrossRef111
Barter, Philip J., Caulfield, Mark, Eriksson, Mats, Grundy, Scott M., Kastelein, John J.P., Komajda, Michel, Lopez-Sendon, Jose, Mosca, Lori, Tardif, Jean-Claude, Waters, David D., Shear, Charles L., Revkin, James H., Buhr, Kevin A., Fisher, Marian R., Tall, Alan R., Brewer, Bryan, . (2007) Effects of Torcetrapib in Patients at High Risk for Coronary Events. New England Journal of Medicine 357:21, 2109-2122
Full Text112
Marianne Zeller, David Masson, Michel Farnier, Luc Lorgis, Valérie Deckert, Jean-Paul Pais de Barros, Catherine Desrumaux, Pierre Sicard, Jacques Grober, Denis Blache, Philippe Gambert, Luc Rochette, Yves Cottin, Laurent Lagrost. (2007) High Serum Cholesteryl Ester Transfer Rates and Small High-Density Lipoproteins Are Associated With Young Age in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology 50:20, 1948-1955
CrossRef113
E. Bruckert, B. Hansel. (2007) HDL-c is a powerful lipid predictor of cardiovascular diseases. International Journal of Clinical Practice 61:11, 1905-1913
CrossRef114
Rebecca L Pollex, Robert A Hegele. (2007) Genetic determinants of plasma lipoproteins. Nature Clinical Practice Cardiovascular Medicine 4:11, 600-609
CrossRef115
Harold E Bays, Ronald B Goldberg. (2007) The ???Forgotten??? Bile Acid Sequestrants: Is Now a Good Time to Remember?. American Journal of Therapeutics 14:6, 567-580
CrossRef116
Geary W. Olsen, Larry R. Zobel. (2007) Assessment of lipid, hepatic, and thyroid parameters with serum perfluorooctanoate (PFOA) concentrations in fluorochemical production workers. International Archives of Occupational and Environmental Health 81:2, 231-246
CrossRef117
Stefan P.J. Dullens, Jogchum Plat, Ronald P. Mensink. (2007) Increasing apoA-I production as a target for CHD risk reduction. Nutrition, Metabolism and Cardiovascular Diseases 17:8, 616-628
CrossRef118
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernández Mijares, Alipio Mangas Rojas, Luis Masana Marín, Jesús Millan Nuñez-Cortés, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Pérez Jimenez, Xavier Pintó, Ignacio Plaza, Juan Rubiés, Manuel Zúñiga. (2007) Dislipemia del síndrome metabólico. Documento sumario del Foro-HDL. Clínica e Investigación en Arteriosclerosis 19:5, 252-263
CrossRef119
Ching-Chu Chen, Tsai-Chung Li, Chia-Ing Li, Chiu-Shong Liu, Wen-Yuan Lin, Ming-Tsang Wu, Ming-May Lai, Cheng-Chieh Lin. (2007) The relationship between visfatin levels and anthropometric and metabolic parameters: association with cholesterol levels in women. Metabolism 56:9, 1216-1220
CrossRef120
Michael H. Davidson. (2007) Targeting High-Density Lipoprotein Cholesterol in the Management of Cardiovascular Disease. The American Heart Hospital Journal 5:4, 210-216
CrossRef121
Anne Carol Goldberg. (2007) Combination therapy of dyslipidemia. Current Treatment Options in Cardiovascular Medicine 9:4, 249-258
CrossRef122
Jeffrey M. Saland, Henry N. Ginsberg. (2007) Lipoprotein metabolism in chronic renal insufficiency. Pediatric Nephrology 22:8, 1095-1112
CrossRef123
&NA;. (2007) Individualisation of treatment regimens and goals is recommended for managing familial dyslipidaemias. Drugs & Therapy Perspectives 23:7, 12-19
CrossRef124
K. K. Ray, C. P. Cannon, E. Braunwald. (2007) Recent trials of lipid lowering. International Journal of Clinical Practice 61:7, 1145-1159
CrossRef125
Ernst J Schaefer, Bela F Asztalos. (2007) Where are we with high-density lipoprotein raising and inhibition of cholesteryl ester transfer for heart disease risk reduction?. Current Opinion in Cardiology 22:4, 373-378
CrossRef126
Xun Wang, Daniel J Rader. (2007) Molecular regulation of macrophage reverse cholesterol transport. Current Opinion in Cardiology 22:4, 368-372
CrossRef127
John Carlquist, Jeffrey L Anderson. (2007) Inconsistencies in the genetic prediction of HDL cholesterol versus atherosclerosis. Current Opinion in Cardiology 22:4, 352-358
CrossRef128
Peter P Toth. (2007) Torcetrapib and atherosclerosis: what happened and where do we go from here?. Future Lipidology 2:3, 277-284
CrossRef129
J Rumi Jaumdally, Chetan Varma, Gregory YH Lip. (2007) Statin therapy in South-Asian patients: clinical implications beyond lipid lowering?. Expert Opinion on Pharmacotherapy 8:9, 1235-1243
CrossRef130
Jennifer G Robinson, Michael H Davidson. (2007) Investigational drugs targeting HDL-C metabolism and reverse cholesterol transport. Future Lipidology 2:3, 285-301
CrossRef131
Yuzo Hayashi, Kenji Okumura, Hideo Matsui, Akiko Imamura, Manabu Miura, Ryotaro Takahashi, Ryuichiro Murakami, Yasuhiro Ogawa, Yasushi Numaguchi, Toyoaki Murohara. (2007) Impact of low-density lipoprotein particle size on carotid intima-media thickness in patients with type 2 diabetes mellitus. Metabolism 56:5, 608-613
CrossRef132
Anne-Mette Lebech, Niels Wiinberg, Ulrik Sloth Kristoffersen, Birger Hesse, Claus Leth Petersen, Jan Gerstoft, Andreas Kjær. (2007) Carotid intima?media thickness in HIV patients treated with antiretroviral therapy. Clinical Physiology and Functional Imaging 27:3, 173-179
CrossRef133
Benjamin D. Horne, Nicola J. Camp, Jeffrey L. Anderson, Chrissa P. Mower, Jessica L. Clarke, Matthew J. Kolek, John F. Carlquist. (2007) Multiple Less Common Genetic Variants Explain the Association of the Cholesteryl Ester Transfer Protein Gene With Coronary Artery Disease. Journal of the American College of Cardiology 49:20, 2053-2060
CrossRef134
Jeffrey J. Link, Anand Rohatgi, James A. de Lemos. (2007) HDL Cholesterol: Physiology, Pathophysiology, and Management. Current Problems in Cardiology 32:5, 268-314
CrossRef135
Kastelein, John J.P., van Leuven, Sander I., Burgess, Leslie, Evans, Greg W., Kuivenhoven, Jan A., Barter, Philip J., Revkin, James H., Grobbee, Diederick E., Riley, Ward A., Shear, Charles L., Duggan, William T., Bots, Michiel L., . (2007) Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia. New England Journal of Medicine 356:16, 1620-1630
Full Text136
John J. P. Kastelein, Sander I. van Leuven, Gregory W. Evans, Ward A. Riley, James H. Revkin, Charles L. Shear, Michiel L. Bots. (2007) Designs of RADIANCE 1 and 2:carotid ultrasound studies comparing the effects of torcetrapib/atorvastatin with atorvastatin alone on atherosclerosis*. Current Medical Research and Opinion 23:4, 885-894
CrossRef137
Karim Harchaoui, Wim A. Steeg, Erik S. G. Stroes, John J. P. Kastelein. (2007) The role of CETP inhibition in dyslipidemia. Current Atherosclerosis Reports 9:2, 125-133
CrossRef138
Nissen, Steven E., Tardif, Jean-Claude, Nicholls, Stephen J., Revkin, James H., Shear, Charles L., Duggan, William T., Ruzyllo, Witold, Bachinsky, William B., Lasala, Gabriel P., Tuzcu, E. Murat, . (2007) Effect of Torcetrapib on the Progression of Coronary Atherosclerosis. New England Journal of Medicine 356:13, 1304-1316
Full Text139
Richard C. Becker. (2007) Off-target properties of pharmacotherapy and the importance of mechanistic investigations in early clinical phase drug development. Journal of Thrombosis and Thrombolysis 23:2, 159-161
CrossRef140
Navin K Kapur. (2007) Rosuvastatin: a highly potent statin for the prevention and management of coronary artery disease. Expert Review of Cardiovascular Therapy 5:2, 161-175
CrossRef141
Oliver Rau, Heiko Zettl, Laura Nicoleta Popescu, Dieter Steinhilber, Manfred Schubert-Zsilavecz. (2007) NeueTargets und Wirkstoffe zur Behandlung von Fettstoffwechselstörungen: Arzneistoffe in der Pipeline. Pharmazie in unserer Zeit 36:2, 142-148
CrossRef142
Ngoc-Anh Le, Mary F. Walter. (2007) Intrinsic enzymes of high-density lipoprotein. Journal of Clinical Lipidology 1:1, 20-30
CrossRef143
Muredach P. Reilly, Alan R. Tall. (2007) HDL proteomics: pot of gold or Pandora’s box?. Journal of Clinical Investigation 117:3, 595-598
CrossRef144
R. P. F. Dullaart, G. M. Dallinga-Thie, B. H. R. Wolffenbuttel, A. van Tol. (2007) CETP inhibition in cardiovascular risk management: a critical appraisal. European Journal of Clinical Investigation 37:2, 90-98
CrossRef145
Xiayang Qiu, Anil Mistry, Mark J Ammirati, Boris A Chrunyk, Ronald W Clark, Yang Cong, Jeffrey S Culp, Dennis E Danley, Thomas B Freeman, Kieran F Geoghegan, Matthew C Griffor, Steven J Hawrylik, Cheryl M Hayward, Preston Hensley, Lise R Hoth, George A Karam, Maruja E Lira, David B Lloyd, Katherine M McGrath, Kim J Stutzman-Engwall, Ann K Subashi, Timothy A Subashi, John F Thompson, Ing-Kae Wang, Honglei Zhao, Andrew P Seddon. (2007) Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. Nature Structural & Molecular Biology 14:2, 106-113
CrossRef146
Prediman K. Shah. (2007) Emerging HDL-based therapies for atherothrombotic vascular disease. Current Treatment Options in Cardiovascular Medicine 9:1, 60-70
CrossRef147
Christine M. Hegedus, Christine F. Skibola, Paige Bracci, Elizabeth A. Holly, Martyn T. Smith. (2007) Screening the human serum proteome for genotype–phenotype associations: An analysis of theIL6 –174G>C polymorphism. PROTEOMICS 7:4, 548-557
CrossRef148
Cesare R Sirtori. (2007) High-density lipoprotein: therapeutic target, 1 year on. Future Lipidology 2:1, 1-4
CrossRef149
Daniel J Rader. (2007) Mechanisms of Disease: HDL metabolism as a target for novel therapies. Nature Clinical Practice Cardiovascular Medicine 4:2, 102-109
CrossRef150
Juan Ascaso, Pedro Gonzalez Santos, Antonio Hernandez Mijares, Alipio Mangas Rojas, Luis Masana, Jesus Millan, Luis Felipe Pallardo, Juan Pedro-Botet, Francisco Perez Jimenez, Xavier Pint??, Ignacio Plaza, Juan Rubi??s, Manuel Z????iga. (2007) Management of Dyslipidemia in the Metabolic Syndrome. American Journal of Cardiovascular Drugs 7:1, 39-58
CrossRef151
Irene F Gazi, Vasilis Tsimihodimos, Alexandros D Tselepis, Moses Elisaf, Dimitri P Mikhailidis. (2007) Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles. Expert Opinion on Biological Therapy 7:1, 53-72
CrossRef152
Shinichiro UEDA. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:5, 295-298
CrossRef153
Shin-ichiro Miura, Keijiro Saku. (2007) Therapies for Raising High-density Lipoprotein Cholesterol. Internal Medicine 46:7, 339-340
CrossRef154
Lloyd W. Klein. (2007) Atherosclerosis Regression, Vascular Remodeling, and Plaque Stabilization. Journal of the American College of Cardiology 49:2, 271-273
CrossRef155
James M. McKenney, John A. Hoekstra. (2007) Will torcetrapib be the next big thing in coronary heart disease risk reduction?. Current Atherosclerosis Reports 9:1, 48-56
CrossRef156
Alexander Chernobelsky, M. Dominique Ashen, Roger S Blumenthal, Neil L. Coplan. (2007) High-Density Lipoprotein Cholesterol: A Potential Therapeutic Target for Prevention of Coronary Artery Disease. Preventive Cardiology 10:1, 26-30
CrossRef157
Benjamin Ansell, F. D. Richard Hobbs. (2006) The potential for CETP inhibition to reduce cardiovascular disease risk. Current Medical Research and Opinion 22:12, 2467-2478
CrossRef158
Daniel J. Rader. (2006) Molecular regulation of HDL metabolism and function: implications for novel therapies. Journal of Clinical Investigation 116:12, 3090-3100
CrossRef159
Michiel L. Bots. (2006) Carotid intima-media thickness as a surrogate marker for cardiovascular disease in intervention studies. Current Medical Research and Opinion 22:11, 2181-2190
CrossRef160
Michael H. Davidson, James M. McKenney, Charles L. Shear, James H. Revkin. (2006) Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels. Journal of the American College of Cardiology 48:9, 1774-1781
CrossRef161
Richard V. Milani, Carl J. Lavie. (2006) Cholesteryl Ester Transfer Protein Inhibition. Journal of the American College of Cardiology 48:9, 1791-1792
CrossRef162
2006. Post-Myocardial Infarction. .
CrossRef163
Belinda A Cutri, Neil J Hime, Stephen J Nicholls. (2006) High-density lipoproteins: an emerging target in the prevention of cardiovascular disease. Cell Research 16:10, 799-808
CrossRef164
Lars A Carlson. (2006) Nicotinic acid and other therapies for raising high-density lipoprotein. Current Opinion in Internal Medicine 5:5, 444-452
CrossRef165
Peter P Toth, Antonio M Gotto. 2006. High-Density Lipoprotein Cholesterol. , 295-340.
CrossRef166
M. John Chapman. (2006) Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacology & Therapeutics 111:3, 893-908
CrossRef167
Benoit Pourcet, Jean-Charles Fruchart, Bart Staels, Corine Glineur. (2006) Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of Type 2 diabetes and atherosclerosis. Expert Opinion on Emerging Drugs 11:3, 379-401
CrossRef168
Natalie Khuseyinova, Wolfgang Koenig. (2006) Apolipoprotein A-I and risk for cardiovascular diseases. Current Atherosclerosis Reports 8:5, 365-373
CrossRef169
Monte Malach, Pascal James Imperato. (2006) Acute Myocardial Infarction and Acute Coronary Syndrome: Then and Now (1950?2005). Preventive Cardiology 9:4, 228-234
CrossRef170
(2006) Guía sobre el manejo de la angina estable. Versión resumida. Revista Española de Cardiología 59:9, 919-970
CrossRef171
Ernst J Schaefer, Bela F Asztalos. (2006) Cholesteryl ester transfer protein inhibition, high-density lipoprotein metabolism and heart disease risk reduction. Current Opinion in Lipidology 17:4, 394-398
CrossRef172
Anthony S Wierzbicki. (2006) Future approaches to reducing low-density lipoprotein cholesterol. Future Lipidology 1:4, 463-476
CrossRef173
Alberto de Luis, Ingrid Roca, Tamara Jiménez, Maite Sastre, Margarita Lladó, F. Javier Poza, Fernando Espada, Àngels Martos. (2006) Tratamiento de los factores de riesgo cardiovascular en pacientes con accidente vascular cerebral. Clínica e Investigación en Arteriosclerosis 18:4, 115-120
CrossRef174
Stephen D Wiviott, Christopher P Cannon. (2006) Update on lipid-lowering therapy and LDL-cholesterol targets. Nature Clinical Practice Cardiovascular Medicine 3:8, 424-436
CrossRef175
Jean-Claude Tardif. (2006) Prevention challenges: The era of atherosclerosis regression. Canadian Journal of Cardiology 22, 27C-30C
CrossRef176
Monica Gomaraschi, Laura Calabresi, Guido Franceschini. (2006) High-density lipoproteins: a therapeutic target for atherosclerotic cardiovascular disease. Expert Opinion on Therapeutic Targets 10:4, 561-572
CrossRef177
Yasumichi Arai, Nobuyoshi Hirose. (2006) Aging and high-density lipoprotein metabolism. Aging Health 2:4, 611-621
CrossRef178
P. MARSCHANG, A. SANDHOFER, A. RITSCH, I. FIŜER, E. KVAS, J. R. PATSCH. (2006) Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin. Journal of Internal Medicine 260:2, 151-159
CrossRef179
Hiroshi Mabuchi, Akihiro Inazu. (2006) Cholesteryl ester transfer protein inhibitors: new strategies for raising high-density lipoprotein cholesterol. Future Lipidology 1:4, 487-500
CrossRef180
Ernst J Schaefer, Bela F Asztalos. (2006) Should we target HDL-cholesterol to reduce coronary heart disease risk?. Nature Clinical Practice Endocrinology & Metabolism 2:7, 358-359
CrossRef181
Michel R. Langlois, Victor H. Blaton. (2006) Historical milestones in measurement of HDL-cholesterol: Impact on clinical and laboratory practice. Clinica Chimica Acta 369:2, 168-178
CrossRef182
Zari Dastani, James C Engert, Jacques Genest, Michel Marcil. (2006) Genetics of high-density lipoproteins. Current Opinion in Cardiology 21:4, 329-335
CrossRef183
Manfredi Rizzo, Kaspar Berneis. (2006) The Clinical Relevance of Low-Density-Lipoproteins Size Modulation by Statins. Cardiovascular Drugs and Therapy 20:3, 205-217
CrossRef184
James A Sikorski. (2006) Cholesteryl ester transfer protein inhibitors as potential new therapies for coronary artery disease. Expert Opinion on Therapeutic Patents 16:6, 753-772
CrossRef185
F. Civeira, E. Bustamante, E. Jarauta, E. Meriño-Ibarra. (2006) Lipoproteínas clásicas, terapéuticas modernas. Farmacología de las lipoproteínas de alta densidad. Clínica e Investigación en Arteriosclerosis 18, 10-19
CrossRef186
Xian-Cheng Jiang, Hong-Wen Zhou. (2006) Plasma lipid transfer proteins. Current Opinion in Lipidology 17:3, 302-308
CrossRef187
Philip T Rodgers, Dawn C Fuke. (2006) New and Emerging Strategies for Reducing Cardiometabolic Risk Factors. Pharmacotherapy 26:5part2, 13S-31S
CrossRef188
O. FAERGEMAN. (2006) Introduction: Apolipoproteins and guidelines for prevention of cardiovascular disease. Journal of Internal Medicine 259:5, 434-436
CrossRef189
Anton Sandhofer, Susanne Kaser, Andreas Ritsch, Markus Laimer, Julia Engl, Bernhard Paulweber, Josef R. Patsch, Christoph F. Ebenbichler. (2006) Cholesteryl Ester Transfer Protein in Metabolic Syndrome*. Obesity 14:5, 812-818
CrossRef190
Stuart T Haines, Dawn C Fuke, Dan Lender, Philip T Rodgers, Suzanne K Sysko. (2006) Evaluating and Treating Cardiometabolic Risk Factors: A Case Discussion. Pharmacotherapy 26:5part2, 32S-41S
CrossRef191
V. CHARLTON-MENYS, P. DURRINGTON. (2006) Apolipoproteins AI and B as therapeutic targets. Journal of Internal Medicine 259:5, 462-472
CrossRef192
F. Briand, T. Magot, M. Krempf, P. Nguyen, K. Ouguerram. (2006) Effects of atorvastatin on high-density lipoprotein apolipoprotein A-I metabolism in dogs. European Journal of Clinical Investigation 36:4, 224-230
CrossRef193
Ryan R. Brinkman, Marie-Pierre Dubé, Guy A. Rouleau, Andrew C. Orr, Mark E. Samuels. (2006) Human monogenic disorders — a source of novel drug targets. Nature Reviews Genetics 7:4, 249-260
CrossRef194
Vassilis I. Zannis, Angeliki Chroni, Monty Krieger. (2006) Role of apoA-I, ABCA1, LCAT, and SR-BI in the biogenesis of HDL. Journal of Molecular Medicine 84:4, 276-294
CrossRef195
Marta Marchesi, Cesare R Sirtori. (2006) Therapeutic use of the high-density lipoprotein protein and peptides. Expert Opinion on Investigational Drugs 15:3, 227-241
CrossRef196
Cinzia Sarti, John Gallagher. (2006) The metabolic syndrome. Journal of Diabetes and its Complications 20:2, 121-132
CrossRef197
Stephen J. Nicholls, E. Murat Tuzcu, Ilke Sipahi, Paul Schoenhagen, Tim Crowe, Samir Kapadia, Steven E. Nissen. (2006) Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano. Journal of the American College of Cardiology 47:5, 992-997
CrossRef198
Anatol Kontush, M John Chapman. (2006) Antiatherogenic small, dense HDL—guardian angel of the arterial wall?. Nature Clinical Practice Cardiovascular Medicine 3:3, 144-153
CrossRef199
John R Burnett, Gerald F Watts. (2006) New therapies for familial hypercholesterolemia. Expert Opinion on Therapeutic Patents 16:3, 349-361
CrossRef200
Dani Bercovich, Yechiel Friedlander, Sigal Korem, Asaf Houminer, Amnon Hoffman, Lilach Kleinberg, Chen Shochat, Eran Leitersdorf, Vardiella Meiner. (2006) The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis 185:1, 97-107
CrossRef201
Andrew C. Li, Wulf Palinski. (2006) PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS: How Their Effects on Macrophages Can Lead to the Development of a New Drug Therapy Against Atherosclerosis. Annual Review of Pharmacology and Toxicology 46:1, 1-39
CrossRef202
Xavier Pintó. (2006) Las estatinas, los hábitos de vida y el tratamiento de la hipercolesterolemia: los tiempos cambian y los criterios también. Medicina Clínica 126:6, 217-219
CrossRef203
Philip J. Barter, John J.P. Kastelein. (2006) Targeting Cholesteryl Ester Transfer Protein for the Prevention and Management of Cardiovascular Disease. Journal of the American College of Cardiology 47:3, 492-499
CrossRef204
Francisco Rodríguez Esparragón, Yaridé Hernández Trujillo, Antonio Macías Reyes, Enrique Hernández Ortega, Alfonso Medina, José C. Rodríguez Pérez. (2006) Sobre los genes paraoxonasa-1 y SR-B1, y su importancia en la aterosclerosis. Revista Española de Cardiología 59:2, 154-164
CrossRef205
Simon W. Beaven, Peter Tontonoz. (2006) Nuclear Receptors in Lipid Metabolism: Targeting the Heart of Dyslipidemia. Annual Review of Medicine 57:1, 313-329
CrossRef206
Jeffrey T Kuvin, Alawi A Alsheikh-Ali, Richard H Karas. (2006) High-Density Lipoprotein Cholesterol-Raising Strategies. Journal of Cardiovascular Pharmacology 47:2, 196-204
CrossRef207
Sheila A Doggrell. (2006) Inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease. Expert Opinion on Investigational Drugs 15:2, 99-106
CrossRef208
Dick C Chan, P Hugh R Barrett, Gerald F Watts. (2006) Recent studies of lipoprotein kinetics in the metabolic syndrome and related disorders. Current Opinion in Lipidology 17:1, 28-36
CrossRef209
Tomonori Okamura, Takehito Hayakawa, Takashi Kadowaki, Yoshikuni Kita, Akira Okayama, Hirotsugu Ueshima. (2006) The inverse relationship between serum high-density lipoprotein cholesterol level and all-cause mortality in a 9.6-year follow-up study in the Japanese general population. Atherosclerosis 184:1, 143-150
CrossRef210
Tiziana Sampietro, Federico Bigazzi, Mariarita Puntoni, Alberto Bionda. (2006) HDL inflammation and atherosclerosis: current and future perspectives. Future Cardiology 2:1, 37-48
CrossRef211
Sahar B Hachem, Arshag D Mooradian. (2006) Familial Dyslipidaemias. Drugs 66:15, 1949-1969
CrossRef212
Danielle Duffy, Daniel J. Rader. (2006) High-Density Lipoprotein Cholesterol Therapies. Journal of Cardiopulmonary Rehabilitation 26:1, 1-8
CrossRef213
Bela F. Asztalos, Ernst J. Schaefer, Katalin V. Horvath, Caitlin E. Cox, Sally Skinner, Jul Gerrior, Sherwood L. Gorbach, Christine Wanke. (2006) Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients. Atherosclerosis 184:1, 72-77
CrossRef214
Anup K. Sabharwal, Jeffrey B. Boord. (2006) Low-density lipoprotein reduction: Is the risk worth the benefit?. Current Atherosclerosis Reports 8:1, 19-25
CrossRef215
Kumar Rajamani, Seemant Chaturvedi. (2006) New strategies in the medical treatment of carotid artery disease. Current Cardiology Reports 8:1, 33-37
CrossRef216
Michael Schachter. (2005) Strategies for Modifying High-Density Lipoprotein Cholesterol: A Role for Nicotinic Acid. Cardiovascular Drugs and Therapy 19:6, 415-422
CrossRef217
Benjamin J. Ansell, Karol E. Watson, Alan M. Fogelman, Mohamad Navab, Gregg C. Fonarow. (2005) High-Density Lipoprotein Function. Journal of the American College of Cardiology 46:10, 1792-1798
CrossRef218
Jerzy-Roch Nofer, Michael Walter, Gerd Assmann. (2005) Current understanding of the role of high-density lipoproteins in atherosclerosis and senescence. Expert Review of Cardiovascular Therapy 3:6, 1071-1086
CrossRef219
Kathryn Wood Holmes, Peter Oscar Kwiterovich. (2005) Treatment of dyslipidemia in children and adolescents. Current Cardiology Reports 7:6, 445-456
CrossRef220
Kausik K Ray, Christopher P Cannon. (2005) Optimal goals for statin use in patients with coronary artery disease. Current Opinion in Cardiology 20:6, 525-529
CrossRef221
Peter Libby. (2005) The Forgotten Majority. Journal of the American College of Cardiology 46:7, 1225-1228
CrossRef222
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef223
Qi Gaofu, Long Jun, Zhao Xiuyun, Liu Wentao, Wu Jie, Liu Jingjing. (2005) Antibody against cholesteryl ester transfer protein (CETP) elicited by a recombinant chimeric enzyme vaccine attenuated atherosclerosis in a rabbit model. Life Sciences 77:21, 2690-2702
CrossRef224
C Daniel Meyers, Moti L Kashyap. (2005) Pharmacologic augmentation of high-density lipoproteins: mechanisms of currently available and emerging therapies. Current Opinion in Internal Medicine 4:5, 517-522
CrossRef225
Ashen, M. Dominique, Blumenthal, Roger S., . (2005) Low HDL Cholesterol Levels. New England Journal of Medicine 353:12, 1252-1260
Full Text226
Harold Bays, James McKenney, Michael Davidson. (2005) Torcetrapib/atorvastatin combination therapy. Expert Review of Cardiovascular Therapy 3:5, 789-820
CrossRef227
Rebecca J Cheung, Matthew K Ito. (2005) Clinical utility of extended-release niacin: update and summary. Future Cardiology 1:5, 571-578
CrossRef228
Robert P. Giugliano, Eugene Braunwald. (2005) The Year in Non
ST-Segment Elevation Acute Coronary Syndromes. Journal of the American College of Cardiology 46:5, 906-919
CrossRef229
U Hodoğlugil, DW Williamson, Y Huang, RW Mahley. (2005) An interaction between the TaqIB polymorphism of cholesterol ester transfer protein and smoking is associated with changes in plasma high-density lipoprotein cholesterol levels in Turks. Clinical Genetics 68:2, 118-127
CrossRef230
David Brückner, Frank-Thorsten Hafner, Volkhart Li, Carsten Schmeck, Joachim Telser, Alexandros Vakalopoulos, Gabriele Wirtz. (2005) Dibenzodioxocinones—A new class of CETP inhibitors. Bioorganic & Medicinal Chemistry Letters 15:15, 3611-3614
CrossRef231
Robert S Rosenson. (2005) Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities. Current Opinion in Cardiology 20:4, 313-317
CrossRef232
Danielle Duffy, Daniel J Rader. (2005) Drugs in development: targeting high-density lipoprotein metabolism and reverse cholesterol transport. Current Opinion in Cardiology 20:4, 301-306
CrossRef233
Avorn, Jerry, . (2005) Torcetrapib and Atorvastatin — Should Marketing Drive the Research Agenda?. New England Journal of Medicine 352:25, 2573-2576
Full Text234
Qi Gaofu, Long Jun, Yang Xin, Liu Wentao, Wu Jie, Zhao Xiuyun, Liu Jingjing. (2005) Vaccinating Rabbits with a Cholesteryl Ester Transfer Protein (CETP) B-Cell Epitope Carried by Heat Shock Protein-65 (HSP65) for Inducing Anti-CETP Antibodies and Reducing Aortic Lesions In Vivo. Journal of Cardiovascular Pharmacology 45:6, 591-598
CrossRef235
Stanley S. Levinson. (2005) Brief review and critical examination of the use of hs-CRP for cardiac risk assessment with the conclusion that it is premature to use this test. Clinica Chimica Acta 356:1-2, 1-8
CrossRef236
Alawi A. Alsheikh-Ali, Jeffrey T. Kuvin, Richard H. Karas. (2005) High-density lipoprotein cholesterol in the cardiovascular equation: Does the “good” still count?. Atherosclerosis 180:2, 217-223
CrossRef237
Stephen J Nicholls, Kerry-Anne Rye, Philip J Barter. (2005) High-density lipoproteins as therapeutic targets. Current Opinion in Lipidology 16:3, 345-349
CrossRef238
Stuart A Cook, Tim Aitman, Rossi P Naoumova. (2005) Therapy Insight: heart disease and the insulin-resistant patient. Nature Clinical Practice Cardiovascular Medicine 2:5, 252-260
CrossRef239
Mahmoud Alawadhi, George Thanassoulis, Michel Marcil, Jacques Genest. (2005) Genetic lipoprotein disorders and coronary atherosclerosis. Current Atherosclerosis Reports 7:3, 196-203
CrossRef240
Xiaosong Wang, Beverly Paigen. (2005) Genome-wide search for new genes controlling plasma lipid concentrations in mice and humans. Current Opinion in Lipidology 16:2, 127-137
CrossRef241
G Kees Hovingh, Eric de Groot, Wim van der Steeg, S Matthijs Boekholdt, Barbara A Hutten, Jan Albert Kuivenhoven, John JP Kastelein. (2005) Inherited disorders of HDL metabolism and atherosclerosis. Current Opinion in Lipidology 16:2, 139-145
CrossRef242
Dhruv Kazi, John A. Farmer. (2005) Raising high-density lipoprotein cholesterol: Innovative strategies against an old adversary. Current Atherosclerosis Reports 7:2, 88-94
CrossRef243
Rakesh S Birjmohun, Erik SG Stroes, John JP Kastelein. (2005) Future strategies in the management of dyslipidemia. Future Cardiology 1:2, 127-130
CrossRef244
Patrick Linsel-Nitschke, Alan R. Tall. (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nature Reviews Drug Discovery 4:3, 193-205
CrossRef245
A. C. M. Vingerhoeds. (2005) Nieuwe hoop voor patiënten met een laag HDL-gehalte. Medisch-Farmaceutische Mededelingen 43:2, 46-46
CrossRef246
O. Stein, Y. Stein. (2005) Lipid transfer proteins (LTP) and atherosclerosis. Atherosclerosis 178:2, 217-230
CrossRef247
Benjamin J. Ansell. (2005) Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports 7:1, 29-33
CrossRef248
Erik Stroes. (2005) Statins and LDL‐cholesterol lowering: an overview. Current Medical Research and Opinion 21:s6, S9-S16
CrossRef249
Wolfgang Bocksch, Suzanne Fateh-Moghadam, Sonja Huehns, Michael Schartl. (2005) Influence of Different Lipid-Lowering Strategies on Plaque Volume and Plaque Composition in Patients with Coronary Artery Disease: Role of Intravascular Ultrasound Imaging. Kidney and Blood Pressure Research 28:5-6, 290-294
CrossRef250
WA van der Steeg, JA Kuivenhoven, AH Klerkx, SM Boekholdt, GK Hovingh, JJP Kastelein. (2004) Role of CETP inhibitors in the treatment of dyslipidemia. Current Opinion in Lipidology 15:6, 631-636
CrossRef251
MM Thompson, SC Reed, GW Cockerill. (2004) Therapeutic approaches to raising plasma HDL-cholesterol levels. Nature Clinical Practice Cardiovascular Medicine 1:2, 84-89
CrossRef252
Pedro R. Moreno, Valentin Fuster. (2004) The year in atherothrombosis. Journal of the American College of Cardiology 44:11, 2099-2110
CrossRef253
R. Weitgasser, G. Galvan, L. Malaimare, I. Derflinger, M. Hedegger, J. Lang, B. Iglseder, G. Ladurner, B. Paulweber. (2004) Cholesteryl ester transfer protein TaqIB polymorphism and its relation to parameters of the insulin resistance syndrome in an Austrian cohort. Biomedicine & Pharmacotherapy 58:10, 619-627
CrossRef254
Mohamad Navab, G M Anantharamaiah, Srinivasa T Reddy, Brian J Van Lenten, Geeta Datta, David Garber, Alan M Fogelman. (2004) Human apolipoprotein A-I and A-I mimetic peptides: potential for atherosclerosis reversal. Current Opinion in Lipidology 15:6, 645-649
CrossRef255
Anthony S Wierzbicki. (2004) Lipid-lowering therapies in development. Expert Opinion on Investigational Drugs 13:11, 1405-1418
CrossRef256
Dario Cattaneo, Sara Baldelli, Simona Merlini, Stefania Zenoni, Norberto Perico, Giuseppe Remuzzi. (2004) Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents 14:11, 1553-1566
CrossRef257
A.S. Wierzbicki. (2004) Lipid-altering agents: the future. International Journal of Clinical Practice 58:11, 1063-1072
CrossRef258
Paul Schoenhagen, Timothy Crowe, Murat Tuzcu, Steven E Nissen. (2004) Pharmacologic strategies for the prevention of atherosclerotic plaque progression. Expert Review of Cardiovascular Therapy 2:6, 855-866
CrossRef259
Emma A. Meagher. (2004) Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story. Current Cardiology Reports 6:6, 457-463
CrossRef260
Sheila A Doggrell. (2004) Raising high-density lipoprotein cholesterol with inhibitors of cholesteryl ester transfer protein – a new approach to coronary artery disease. Expert Opinion on Investigational Drugs 13:10, 1365-1368
CrossRef261
Michael H. Criqui, Beatrice A. Golomb. (2004) Low and lowered cholesterol and total mortality
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarly represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 44:5, 1009-1010
CrossRef262
Alan M Fogelman. (2004) When good cholesterol goes bad. Nature Medicine 10:9, 902-903
CrossRef263
Sheila A Doggrell. (2004) Atorvastatin versus pravastatin: intensive versus moderate lipid lowering. Expert Opinion on Pharmacotherapy 5:9, 2025-2028
CrossRef264
Daniel J. Rader. (2004) Inhibition of cholesteryl ester transfer protein activity: A new therapeutic approach to raising high-density lipoprotein. Current Atherosclerosis Reports 6:5, 398-405
CrossRef265
John Morgan, Christina Carey, Anne Lincoff, David Capuzzi. (2004) High-density lipoprotein subfractions and risk of coronary artery disease. Current Atherosclerosis Reports 6:5, 359-365
CrossRef266
Harold E Bays. (2004) Extended-release niacin/lovastatin: the first combination product for dyslipidemia. Expert Review of Cardiovascular Therapy 2:4, 485-501
CrossRef267
Brewer, H. Bryan Jr., . (2004) Increasing HDL Cholesterol Levels. New England Journal of Medicine 350:15, 1491-1494
Full Text268
Ping Fan, Bo Zhang, Syoji Kuroki, Keijiro Saku. (2004) Pitavastatin, a Potent Hydroxymethylglutaryl Coenzyme a Reductase Inhibitor, Increases Cholesterol 7 α-Hydroxylase Gene Expression in HepG2 Cells. Circulation Journal 68:11, 1061-1066
CrossRef269
Frank van Leth, Prahpan Phanuphak, Erik Stroes, Brian Gazzard, Pedro Cahn, François Raffi, Robin Wood, Mark Bloch, Christine Katlama, John J. P. Kastelein, Mauro Schechter, Robert L. Murphy, Andrzej Horban, David B. Hall, Joep M. A. Lange, Peter Reiss. (2004) Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1. PLoS Medicine 1:1, e19
CrossRef
